Wall Street brokerages expect Biopharmx Corp (NYSE:BPMX) to report $30,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Biopharmx Corp’s earnings. The lowest sales estimate is $10,000.00 and the highest is $40,000.00. Biopharmx Corp also reported sales of $30,000.00 in the same quarter last year. The business is scheduled to report its next earnings results on Tuesday, June 13th.

According to Zacks, analysts expect that Biopharmx Corp will report full-year sales of $30,000.00 for the current year, with estimates ranging from $30,000.00 to $3 million. For the next year, analysts forecast that the firm will post sales of $6.74 million per share, with estimates ranging from $50,000.00 to $20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Biopharmx Corp.

Separately, Roth Capital set a $3.00 price objective on shares of Biopharmx Corp and gave the stock a “buy” rating in a research report on Thursday, February 9th.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/05/19/brokerages-expect-biopharmx-corp-bpmx-will-announce-quarterly-sales-of-30000-00.html.

Shares of Biopharmx Corp (NYSE:BPMX) traded up 8.9111% during trading on Friday, reaching $0.4901. 1,462,431 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.46. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $1.22. The stock’s market cap is $33.19 million.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NYSE:BPMX

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.